TAK

Takeda Pharmaceutical Co Ltd ADR

TAK, USA

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

https://www.takeda.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

Semiannual

Rate:

0.32214

Next Payout:

Dec 11, 2025

Yield:

8.9920 %
TAK
stock
TAK

Layoff Watch: How PLTG stock performs in weak economy - July 2025 Opening Moves & Weekly Stock Breakout Alerts moha.gov.vn

Read more →
TAK
stock
TAK

Smart Money: Why BAYAR stock could see breakout soon - July 2025 Decliners & Weekly Top Stock Performers List moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$17.5624

Analyst Picks

Strong Buy

3

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

204.43

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.17 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.08 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

29.24 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.03

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 3.07% of the total shares of Takeda Pharmaceutical Co Ltd ADR

1.

Capital Research Global Investors

(0.421%)

since

2025/06/30

2.

American Funds American Mutual A

(0.4081%)

since

2025/06/30

3.

Capital Group American Mutual Comp

(0.4081%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(0.2413%)

since

2025/06/30

5.

Goldman Sachs Group Inc

(0.1425%)

since

2025/06/30

6.

FMR Inc

(0.1299%)

since

2025/06/30

7.

UBS Group AG

(0.1274%)

since

2025/06/30

8.

Brandes Investment Partners & Co

(0.1175%)

since

2025/06/30

9.

BlackRock Inc

(0.1124%)

since

2025/06/30

10.

Renaissance Technologies Corp

(0.1045%)

since

2025/06/30

11.

Millennium Management LLC

(0.0978%)

since

2025/06/30

12.

First Trust Value Line® Dividend ETF

(0.0827%)

since

2025/08/28

13.

First Trust Advisors L.P.

(0.0824%)

since

2025/06/30

14.

Adage Capital Partners Gp LLC

(0.0802%)

since

2025/06/30

15.

Northern Trust Corp

(0.0643%)

since

2025/06/30

16.

Managed Asset Portfolios, LLC

(0.0471%)

since

2025/06/30

17.

Van Eck Associates Corporation

(0.0422%)

since

2025/06/30

18.

Arrowstreet Capital Limited Partnership

(0.0386%)

since

2025/06/30

19.

VanEck Pharmaceutical ETF

(0.0378%)

since

2025/08/30

20.

Bank of America Corp

(0.0328%)

since

2025/06/30

21.

Wells Fargo & Co

(0.0321%)

since

2025/06/30

22.

Envestnet Asset Management Inc

(0.0279%)

since

2025/06/30

23.

Quantinno Capital Management LP

(0.0252%)

since

2025/06/30

24.

Crossmark Global Holdings, Inc.

(0.023%)

since

2025/06/30

25.

MAP Global Equity Composite

(0.0227%)

since

2025/06/30

26.

Steward Values Enhanced International I

(0.0206%)

since

2025/07/31

27.

Capital Group American Mutual Trust U0

(0.0129%)

since

2025/06/30

28.

MAP Global Balanced Composite

(0.0124%)

since

2025/06/30

29.

Avantis International Equity ETF

(0.0117%)

since

2025/08/30

30.

Quantified Global Fund Investor

(0.0109%)

since

2025/06/30

31.

MAP Global Equity Ex-Options Composite

(0.0095%)

since

2025/06/30

32.

Russell Personalized Core Equity SMA

(0.0068%)

since

2025/06/30

33.

SGI Global Equity

(0.0066%)

since

2025/03/31

34.

ActivePassive International Equity ETF

(0.0064%)

since

2025/08/29

35.

Multi-Manager Intl Eq Strats Instl

(0.0054%)

since

2025/07/31

36.

Catalyst/MAP Global Equity A

(0.005%)

since

2025/06/30

37.

VALMXVL B1

(0.0041%)

since

2025/07/31

38.

Vanguard FTSE All-Wld ex-US ETF

(0.0032%)

since

2025/07/31

39.

Domini Impact Equity Investor

(0.0031%)

since

2025/06/30

40.

Russell Personalized International SMA

(0.0029%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0253

EPS Estimate

0.151

EPS Difference

-0.1763

Surprise Percent

-116.755%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(4)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(6)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(3.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.